How many clinical trials are tracked for Acute Gastroenteritis?

17 trials are tracked, 2 with published results.

Acute Gastroenteritis Research

Acute Gastroenteritis: what the trials found

Several rotavirus vaccines have demonstrated efficacy and immunogenicity in preventing gastroenteritis. A pentavalent live oral rotavirus vaccine showed a significant reduction in the number of participants with rotavirus gastroenteritis of any severity, moderate to severe, or severe cases caused by specific serotypes (p<0.001) ⁹. This same pentavalent vaccine demonstrated significantly higher geometric mean titers for poliovirus types 1, 2, and 3 compared to placebo ⁸, while showing no significant difference in serum anti-rotavirus IgA concentrations ⁸.

Other rotavirus vaccines have shown high rates of seroconversion for anti-rotavirus (RV) IgA antibodies [5, 6] and specific seroconversion responses for RV IgA and neutralizing antibodies ¹⁰. Additionally, the HIL-214 vaccine demonstrated a robust immune response when co-administered with other pediatric vaccines compared to placebo ⁷.

Regarding acute treatment of gastroenteritis, RHB-102 showed significant success in reducing the number of patients who vomited within 24 hours of the first dose (p=0.0166) ⁴. In contrast, LGG did not show a statistically significant difference in duration of diarrhea or modified Vesikari Scale scores ³.

For the clinician treating this condition

Rotavirus vaccines (e.g., pentavalent live oral) are established to significantly reduce the incidence of rotavirus-associated gastroenteritis across various severity levels ⁹.
RhB-102 has shown statistically significant efficacy in reducing vomiting within 24 hours of administration ⁴.
LGG did not demonstrate a statistically significant impact on diarrhea duration or clinical scores in the studied population ³.

AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.